RxDoctor Payments Data

Mark Warner, MD

Pulmonary Disease · Houston, TXNPI 1659531036

Payments from drug & device makers

$8,765in general payments, 2019–2025

Across 25 payments — averaging $350.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$8K
  • Boehringer Ingelheim$152
  • Insmed, Inc.$82
  • Baxter Healthcare$40
  • Mylan Specialty L.p.$20
  • Masimo Corporation$18
  • plus $31 from 2 others
$1,485in research payments, 2019–2025

Across 7 payments — averaging $212.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$1K

What the payments were for

  • Food & beverage$36795%
  • Education$175%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,765 in reported general payments places this provider in the 70th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$47,321
Medicare patients
125
Services billed
367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter89$67,626
Breztri AerosphereBudesonide/Glycopyr/Formoterol52$39,083
Spiriva RespimatTiotropium Bromide37$20,127
Stiolto RespimatTiotropium Br/Olodaterol Hcl24$17,948
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$15,997
Breo ElliptaFluticasone/Vilanterol28$15,127
Incruse ElliptaUmeclidinium Bromide20$7,280
Roflumilast11$3,212
Albuterol Sulfate HfaAlbuterol Sulfate109$2,999
Fluticasone Propionate30$759
Azelastine Hcl17$376
Prednisone40$199
Montelukast Sodium17$181
Azithromycin25$135
Pantoprazole Sodium13$125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$8,422$106,030161 claims
AstraZenecaBreztri Aerosphere$16$39,08352 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$152$38,07561 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →